Mikkael Sekeres

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi request reprint The challenge of acute myeloid leukemia in older patients
    Mikkael A Sekeres
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Curr Opin Oncol 14:24-30. 2002
  2. ncbi request reprint New data with arsenic trioxide in leukemias and myelodysplastic syndromes
    Mikkael A Sekeres
    Cleveland Clinic Taussig Cancer Center, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Clin Lymphoma Myeloma 8:S7-S12. 2007
  3. pmc Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
    Hien K Duong
    Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio 44195, USA
    Clin Interv Aging 4:197-205. 2009
  4. doi request reprint The euphoria of hypomethylating agents in MDS and AML: is it justified?
    Mikkael A Sekeres
    Leukemia Program, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA Electronic address
    Best Pract Res Clin Haematol 26:275-8. 2013
  5. pmc Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
    Azra Raza
    Columbia University Medical Center, New York, NY, USA
    J Hematol Oncol 5:18. 2012
  6. doi request reprint Improving the diagnosis and treatment of patients with myelodysplastic syndromes through a performance improvement initiative
    Mikkael A Sekeres
    Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Leuk Res 37:422-6. 2013
  7. pmc Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
    Mikkael A Sekeres
    Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Blood 120:4945-51. 2012
  8. pmc Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia
    Mikkael A Sekeres
    Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
    Haematologica 98:119-28. 2013
  9. pmc Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
    Yuka Sugimoto
    Department of Translational Hematology and Oncology Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
    J Hematol Oncol 5:4. 2012
  10. doi request reprint How to manage lower-risk myelodysplastic syndromes
    M A Sekeres
    Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Leukemia 26:390-4. 2012

Detail Information

Publications71

  1. ncbi request reprint The challenge of acute myeloid leukemia in older patients
    Mikkael A Sekeres
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Curr Opin Oncol 14:24-30. 2002
    ..Future directions include therapies targeted at immunomodulation, at angiogenesis, and in particular against intracellular signals that promote proliferation at the expense of differentiation...
  2. ncbi request reprint New data with arsenic trioxide in leukemias and myelodysplastic syndromes
    Mikkael A Sekeres
    Cleveland Clinic Taussig Cancer Center, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Clin Lymphoma Myeloma 8:S7-S12. 2007
    ....
  3. pmc Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
    Hien K Duong
    Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio 44195, USA
    Clin Interv Aging 4:197-205. 2009
    ..In this population, GO has an acceptable toxicity and yields response rates approaching 30%. The efficacy of GO as monotherapy and in combination therapy for treatment of both de novo and relapsed AML continues to be investigated...
  4. doi request reprint The euphoria of hypomethylating agents in MDS and AML: is it justified?
    Mikkael A Sekeres
    Leukemia Program, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA Electronic address
    Best Pract Res Clin Haematol 26:275-8. 2013
    ..Neither agent has demonstrated a survival advantage in older AML patients in prospective studies. Reasons for this are explored here along with a recommendation to reconsider clinical trial design endpoints. ..
  5. pmc Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
    Azra Raza
    Columbia University Medical Center, New York, NY, USA
    J Hematol Oncol 5:18. 2012
    ..Ezatiostat, a glutathione S-transferase P1-1 inhibitor, promotes the maturation of hematopoietic progenitors and induces apoptosis in cancer cells...
  6. doi request reprint Improving the diagnosis and treatment of patients with myelodysplastic syndromes through a performance improvement initiative
    Mikkael A Sekeres
    Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Leuk Res 37:422-6. 2013
    ..Improvements related to patient communication and disease education were also observed and support the overall efficacy and value of PI in MDS patient care...
  7. pmc Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
    Mikkael A Sekeres
    Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Blood 120:4945-51. 2012
    ..TET2/DNMT3A/IDH1/2 mutational status was associated with response in a limited number of patients. The lenalidomide/azacitidine combination is well-tolerated and highly active in treating greater-risk MDS...
  8. pmc Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia
    Mikkael A Sekeres
    Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
    Haematologica 98:119-28. 2013
    ....
  9. pmc Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
    Yuka Sugimoto
    Department of Translational Hematology and Oncology Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
    J Hematol Oncol 5:4. 2012
    ..We hypothesized that improved detection of chromosomal abnormalities with new karyotyping tools may better predict response to LEN...
  10. doi request reprint How to manage lower-risk myelodysplastic syndromes
    M A Sekeres
    Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Leukemia 26:390-4. 2012
    ..Newer therapies hold the promise of activity in patients who have failed standard regimens...
  11. pmc A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605
    Mikkael A Sekeres
    Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Blood 118:523-8. 2011
    ..In conclusion, lenalidomide as a single agent has modest activity in older del(5q) AML patients. Southwest Oncology Group Study S0605 is registered at www.clinicaltrials.gov as NCT00352365...
  12. pmc Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey
    Mikkael A Sekeres
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Desk R35, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
    Oncologist 16:904-11. 2011
    ..S. Little information is available regarding how aware MDS patients are of their disease severity, prognosis, and treatment outcomes...
  13. pmc Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes
    Mikkael A Sekeres
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Desk R35, 9500 Euclid Ave, Cleveland, OH 44195, USA
    J Clin Oncol 26:5943-9. 2008
    ..Lenalidomide-induced cytopenias occurring early in treatment may serve as a surrogate marker of clonal suppression and, therefore, may be predictive of a TI response...
  14. ncbi request reprint Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010
    Mikkael A Sekeres
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Ohio 44195, USA
    J Natl Compr Canc Netw 9:57-63. 2011
    ..Erythropoiesis stimulating agents are used by more than 50% of patients, although the use of disease-modifying agents is increasing, and may ultimately have an impact on the number of patients living with MDS...
  15. doi request reprint Arsenic trioxide as a treatment for myelodysplastic syndrome
    Mikkael A Sekeres
    Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Hematol Malig Rep 1:34-8. 2006
    ..MDS patients whose cells express the EVI1 mutation in particular may derive benefit from this therapy...
  16. doi request reprint Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes
    Mikkael A Sekeres
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Cancer 117:992-1000. 2011
    ..Romiplostim is a peptibody protein that augments thrombopoiesis by activating the thrombopoietin receptor...
  17. pmc Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment
    Mikkael A Sekeres
    Myelodysplastic Syndromes Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Blood 114:2575-80. 2009
    ..This article considers some of these issues as they relate to study design, including how to identify certain MDS populations and define disease progression...
  18. doi request reprint A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia
    Mikkael A Sekeres
    Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Cancer 117:1253-61. 2011
    ..AML therapies thus may have activity in MDS. In the current study, phase 2 study data of arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) in CD33-positive patients with MDS and secondary AML (sAML) were presented...
  19. doi request reprint Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes
    Mikkael A Sekeres
    Department of Hematologic Oncology and Blood Disorders, Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Am J Hematol 86:102-3. 2011
    ..We conclude that the addition of lenalidomide to azacitidine provides additional clinical benefit over azacitidine monotherapy...
  20. doi request reprint Are we nearer to curing patients with MDS?
    Mikkael A Sekeres
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, OH 44195, USA
    Best Pract Res Clin Haematol 23:481-7. 2010
    ..Treatment options range from supportive care, to disease-modifying chemotherapeutic agents, to stem cell transplantation, to therapies that may affect quality of life, improve survival, or even cure the disease...
  21. pmc Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys
    Mikkael A Sekeres
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    J Natl Cancer Inst 100:1542-51. 2008
    ..We describe these characteristics in a large group of recently diagnosed and existing (ie, established) MDS patients...
  22. pmc Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients
    Mikkael A Sekeres
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Blood 113:28-36. 2009
    ..AML therapy should be initiated immediately in younger patients. Delaying treatment does not seem harmful in older patients, allowing individualized approaches...
  23. pmc Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes
    Mikkael A Sekeres
    Myelodsyplastic Syndromes Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Desk R35, 9500 Euclid Ave, Cleveland, OH 44195, USA
    J Clin Oncol 28:2253-8. 2010
    ..These agents may complement each other by targeting both the bone marrow microenvironment and hypomethylating action on the malignant clone...
  24. ncbi request reprint The avastin story
    Mikkael A Sekeres
    Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
    N Engl J Med 365:1454-5. 2011
    ..But neither article covered a basic, patient-focused theme that we, the oncologists on the panel, considered: that of giving hope - but not false hope. Avastin received accelerated approval from . . ...
  25. ncbi request reprint The impact of a physician awareness group and the first year of training on hematology-oncology fellows
    Mikkael A Sekeres
    Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Desk R35, 9500 Euclid Ave, Cleveland, OH 44195, USA
    J Clin Oncol 21:3676-82. 2003
    ..To assess the impact of a Balint-like physician awareness group on hematology-oncology fellows' attitudes and measure changes in attitudes during the first fellowship year...
  26. ncbi request reprint Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome
    M A Sekeres
    Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Leukemia 18:809-16. 2004
    ..Regardless of treatment choice, patients report not being offered treatment options and overestimate their chances of cure. In IC patients, QOL decreases during hospitalization but rebounds after discharge...
  27. ncbi request reprint Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia
    Mikkael A Sekeres
    Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Desk R35, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Blood 103:4036-42. 2004
    ..African Americans and whites with AML differ with respect to important prognostic factors. African American men have worse CR rates and overall survival than whites and African American women, and should be considered a poor-risk group...
  28. ncbi request reprint Arsenic trioxide as a treatment for myelodysplastic syndrome
    Mikkael A Sekeres
    Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Hematol Rep 4:59-63. 2005
    ..MDS patients whose cells express the EVI1 mutation in particular may derive benefit from this therapy...
  29. ncbi request reprint Alternative treatments for myelodysplastic syndromes
    Mikkael Sekeres
    Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Semin Hematol 42:S32-7. 2005
    ..Herein, we summarize an array of novel treatments in development for the management of MDS...
  30. ncbi request reprint The myelodysplastic syndromes
    Mikkael A Sekeres
    Cleveland Clinic Lerner College of Medicine, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Expert Opin Biol Ther 7:369-77. 2007
    ..Agents such as thalidomide, lenalidomide and the hypomethylating drugs 5-azacytidine and decitabine have shown promising efficacy and tolerability in clinical trials, and may represent a springboard for future treatment combinations...
  31. ncbi request reprint Non-transplant therapy for older adults with acute myeloid leukemia
    Mikkael A Sekeres
    Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk R35, Cleveland, OH 44195, USA
    J Natl Compr Canc Netw 4:51-6. 2006
    ..Clinical trials should be considered at every stage of treatment in this group of patients...
  32. ncbi request reprint Immunomodulation in myelodysplastic syndromes
    Mikkael A Sekeres
    Cleveland Clinic Lerner College of Medicine, Department of Hematologic Malignancies and Blood Disorders, Taussig Cancer Center, Cleveland Clinic Foundation, Desk R35, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
    Best Pract Res Clin Haematol 19:757-67. 2006
    ..Agents such as thalidomide, lenalidomide, and infliximab have shown promising efficacy and tolerability in clinical trials, and may represent a springboard for future treatment combinations...
  33. ncbi request reprint A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes
    Mikkael A Sekeres
    Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Cancer 109:1125-32. 2007
    ..For low-risk MDS the optimal initial therapy (GF vs nongrowth factor [NGF] therapies, including differentiation and immunomodulatory agents) based on response rates to NGF and GF and survival, has not been defined...
  34. doi request reprint Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia
    Matt Kalaycio
    Department of Hematologic Malignancies and Blood Disorders, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Am J Hematol 83:831-4. 2008
    ..Our intensive and risk-adapted, stem cell transplant approach to the treatment of patients with AML requires a better definition of risk and does not appear to substantially improve results compared with more standard approaches...
  35. pmc Histone H4 acetylation by immunohistochemistry and prognosis in newly diagnosed adult acute lymphoblastic leukemia (ALL) patients
    Anjali S Advani
    Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, The Cleveland Clinic, Cleveland, OH, USA
    BMC Cancer 10:387. 2010
    ....
  36. doi request reprint Histone H4 acetylation by immunohistochemistry and prognosis in relapsed acute lymphocytic leukaemia (ALL)
    Anjali S Advani
    Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH 44195, USA
    Br J Haematol 153:504-7. 2011
    ..These data provide a rationale for the use of histone deacetylase inhibitors in the treatment of relapsed ALL...
  37. doi request reprint Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia
    Anjali S Advani
    Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, The Cleveland Clinic, Cleveland, OH 44195, USA
    Leuk Lymphoma 49:1560-6. 2008
    ..27, CI (1.04-1.55), p = 0.019] and decreased overall survival [HR 1.34, CI (1.08-1.67), p = 0.009]. Delayed time from IC to PRT (> or =6.6 weeks) was associated with a statistically worse progression-free and overall survival...
  38. doi request reprint A prognostic scoring system for adult patients less than 60 years of age with acute lymphoblastic leukemia in first relapse
    Anjali Advani
    Taussig Cancer Center, The Cleveland Clinic, Cleveland, OH 44195, USA
    Leuk Lymphoma 50:1126-31. 2009
    ..Patients with a prognostic score of greater than 1 have a poor prognosis, even with BMT, and should be considered for treatment with innovative approaches such as Phase 1 clinical trials...
  39. pmc Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
    Ying Jiang
    Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic, OH 44195, USA
    Blood 113:1315-25. 2009
    ..However, the ubiquity, extent, and correlation with disease progression suggest that aberrant DNA methylation is the dominant mechanism for TSG silencing and clonal variation in MDS evolution to AML...
  40. ncbi request reprint Managing patients with low-risk MDS
    Mikkael Sekeres
    Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA
    Clin Adv Hematol Oncol 4:1-10; quiz 11-2. 2006
    ....
  41. doi request reprint Ribosomal S6 kinase and AKT phosphorylation as pharmacodynamic biomarkers in patients with myelodysplastic syndrome treated with RAD001
    Anjali S Advani
    Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH Electronic address
    Clin Lymphoma Myeloma Leuk 14:172-177.e1. 2014
    ....
  42. pmc p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies
    Yogen Saunthararajah
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Semin Oncol 39:97-108. 2012
    ..Decitabine or 5-azacytidine dose and schedule can be rationalized to emphasize this mechanism of action, as an alternative or complement to conventional apoptosis-based oncotherapy...
  43. ncbi request reprint Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML
    Anjali S Advani
    Taussig Cancer Center, Leukemia Program, The Cleveland Clinic CCF, Cleveland, OH 44195, USA
    Leuk Res 32:913-8. 2008
    ..Whether inhibiting c-kit in patients with AML will alter prognosis is the basis of ongoing clinical trials...
  44. ncbi request reprint The role of post-remission chemotherapy for older patients with acute myelogenous leukemia
    Rony M Abou-Jawde
    Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Leuk Lymphoma 47:689-95. 2006
    ..21 and P = 0.15, respectively). PRT has not clearly improved survival in older patients with AML, and therefore the routine addition of chemotherapy to older patients in complete remission is not indicated...
  45. doi request reprint Development of a modified surveillance definition of central line-associated bloodstream infections for patients with hematologic malignancies
    Megan J Digiorgio
    Department of Infection Prevention, Quality and Patient Safety Institute, Cleveland, Ohio, USA
    Infect Control Hosp Epidemiol 33:865-8. 2012
    ..To develop a modified surveillance definition of central line-associated bloodstream infection (mCLABSI) specific for our population of patients with hematologic malignancies to better support ongoing improvement efforts at our hospital...
  46. doi request reprint A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia
    Anjali S Advani
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA
    Leuk Res 34:1622-6. 2010
    ..The maximum tolerated dose of IM was 300 mg. The dose-limiting toxicity was Grade 3-4 hepatic toxicity. The CR/CRp rate was 57%. Cytotoxic therapy that includes IM for relapsed AML is well-tolerated and effective...
  47. doi request reprint OCT-2 expression and OCT-2/BOB.1 co-expression predict prognosis in patients with newly diagnosed acute myeloid leukemia
    Anjali S Advani
    Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Leuk Lymphoma 51:606-12. 2010
    ..10, p = 0.036) and a trend toward a worse OS (HR 1.10, p = 0.063). OCT-2 may act as a cell survival factor in AML by mediating expression of downstream targets, such as BCL-2. These results will need to be validated prospectively...
  48. doi request reprint Myelodysplastic syndromes: a practical approach to diagnosis and treatment
    Afsaneh Barzi
    Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Cleve Clin J Med 77:37-44. 2010
    ..MDS are now considered the most common form of leukemia, and in some cases deserve immediate intervention. This review describes common presentations of MDS, optimal diagnostic approaches, and therapies for lower-and higher-risk disease...
  49. ncbi request reprint Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia
    Rachid Baz
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA
    Cancer 110:1752-9. 2007
    ..Earlier clinical trials have yielded conflicting results and possibly a minor survival benefit, often offset by a longer hospitalization time...
  50. pmc High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes
    Ramon Tiu
    Experimental Hematology and Hematopoiesis Section, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Exp Hematol 35:240-51. 2007
    ..Therefore, it is likely that chromosomal defects in myelodysplastic syndromes may be more frequent than predicted by metaphase cytogenetics and new cryptic lesions may be revealed by precise analysis methods...
  51. ncbi request reprint Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes
    Ali Reza Golshayan
    Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA
    Br J Haematol 137:125-32. 2007
    ..Decision tools need to be developed to determine which therapy to choose for patients with low-risk MDS...
  52. ncbi request reprint Myelodysplastic syndromes: more prevalent than we know
    Satinderpal K Sandhu
    Case Western Reserve University School of Medicine, and Senior Health and Wellness Center, MetroHealth Medical Center, Cleveland, Ohio, USA
    Geriatrics 63:10-7. 2008
    ..Comorbidities and functional issues make this disease challenging to diagnose and treat in geriatric patients. This article reviews the epidemiology, classification, and treatment options for MDS...
  53. ncbi request reprint Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic syndromes
    Lukasz P Gondek
    Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA
    Exp Hematol 35:1728-38. 2007
    ..We hypothesize that more precise methods of chromosomal analysis will detect new/additional cryptic lesions in a higher proportion of MDS patients...
  54. pmc FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q)
    Hideki Makishima
    Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA
    Leuk Res 34:447-53. 2010
    ....
  55. pmc New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia
    Ramon V Tiu
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    J Clin Oncol 27:5219-26. 2009
    ..We hypothesized that SNP-A will improve detection of chromosomal defects in AML and that this would enhance the prognostic value of MC...
  56. doi request reprint The epidemiology of myelodysplastic syndromes
    Mikkael A Sekeres
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Hematol Oncol Clin North Am 24:287-94. 2010
    ..The most common risk factors for developing MDS include advanced age, male gender, previous exposure to chemotherapy or radiation therapy, smoking, or, in rare cases, exposure to industrial chemicals...
  57. ncbi request reprint Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia
    Jennifer K Long
    Department of Pharmacy, Clinical Microbiology Section, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Mayo Clin Proc 80:1215-6. 2005
    ..No enterococcal cross-resistance has been reported among daptomycin, linezolid, or quinupristin-dalfopristin, and these agents may be viable alternatives...
  58. doi request reprint Impact of weekend admissions on quality of care and outcomes in patients with acute myeloid leukemia
    Nelli Bejanyan
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Cancer 116:3614-20. 2010
    ..The authors investigated quality of care and clinical outcomes of newly diagnosed acute myeloid leukemia (AML) patients who were hospitalized on weekends versus weekdays and treated with induction chemotherapy...
  59. ncbi request reprint The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromes
    Ramon V Tiu
    Cleveland Clinic Taussig Cancer Center, Department of Hematologic Oncology and Blood Disorders, 9500 Euclid Avenue R35, Cleveland, Ohio 44195, USA
    Expert Opin Biol Ther 8:1021-30. 2008
    ....
  60. pmc Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML
    Lukasz P Gondek
    Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic, OH, USA
    Blood 111:1534-42. 2008
    ..SNP-A-based karyotyping shows superior resolution for chromosomal defects, including UPD. This technique further complements MC to improve clinical prognosis and targeted therapies...
  61. pmc Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies
    Hideki Makishima
    Taussig Cancer Institute R40, 9500 Euclid Ave, Cleveland OH 44195, USA
    J Clin Oncol 27:6109-16. 2009
    ..We examined the role and frequency of Cbl gene family mutations in MPN and related conditions...
  62. ncbi request reprint Impact of socioeconomic status and distance from treatment center on survival in patients receiving remission induction therapy for newly diagnosed acute myeloid leukemia
    Cristina P Rodriguez
    Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, 9500 Euclid Avenue R35, Cleveland, OH 44195, USA
    Leuk Res 32:413-20. 2008
    ..While socioeconomic status (SES) and the distance patients travel to a treatment center (DTC) impact survival of certain solid tumors, little is known of their influence in acute myeloid leukemia (AML)...
  63. ncbi request reprint Thalidomide use and digital gangrene
    Tyler Y Kang
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA
    J Clin Oncol 24:5328. 2006
  64. ncbi request reprint Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts
    Zachary P Nearman
    Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland, Ohio, USA
    Am J Hematol 82:1076-9. 2007
    ....
  65. pmc Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations
    Hadrian Szpurka
    Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
    Leuk Res 34:969-73. 2010
    ..JAK2V617F/MPLW515L mutations were absent in TET2/ASXL1 mutants, indicating that similar clinical phenotype can be produced by various MPN-associated mutations and that additional unifying lesions may be present in RARS-T...
  66. pmc 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies
    Andrew J Dunbar
    Department of Hematologic Oncology and Blood Disorders, Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Cancer Res 68:10349-57. 2008
    ..Acquired mutations of c-Cbl E3 ubiquitin ligase may explain the pathogenesis of a clonal process in a subset of MDS/MPD, including CMML...
  67. doi request reprint Survival and predictors of outcome in patients with acute leukemia admitted to the intensive care unit
    Snehal G Thakkar
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA
    Cancer 112:2233-40. 2008
    ..Predictors of outcome and rates of successful discharge have not been defined for patients with acute leukemia admitted to intensive care units (ICUs) in the US...
  68. ncbi request reprint White blood cell count nadir following remission induction chemotherapy is predictive of outcome in older adults with acute myeloid leukemia
    Hyo Sook Han
    Division of Hematology and Oncology, Sylvester Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA
    Leuk Lymphoma 48:1561-8. 2007
    ..12 x 10(9)/l HR 1.5, 95%CI 0.96 - 2.37, p = 0.08), as predictors of worse outcomes. Time to WBC nadir predicts survival. The absolute WBC nadir value follows a J-curve, with lower value indicating a worse outcome...
  69. ncbi request reprint Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good?
    Mikkael A Sekeres
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612 9497, USA
    Curr Hematol Rep 4:182-5. 2005
    ....
  70. ncbi request reprint Older adults with acute myeloid leukemia
    Mikkael A Sekeres
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Curr Oncol Rep 4:403-9. 2002
    ..Herein we characterize the intrinsic biologic features of AML as it occurs in the older population, review currently available therapeutic approaches, and discuss therapeutic strategies in development...
  71. ncbi request reprint The incidence and impact of thrombocytopenia in myelodysplastic syndromes
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:1705-14. 2007
    ..Many approved and investigational MDS therapies caused or exacerbated preexisting thrombocytopenia. The incidence of severe bleeding in MDS was greater than reported in current guidelines...